新型Cap依赖性内切酶抑制剂玛巴洛沙韦治疗流感的临床研究进展  

Clinical research progress of new Cap-dependent endonuclease inhibitor baloxavir marboxil in treatment of influenza

作　　者：黄光亮 何文娟[1] 赵晓娟[1] 赵永红[1] 崔文彦 刘秀菊[1] HUANG Guang-liang;HE Wen-juan;ZHAO Xiao-juan;ZHAO Yong-hong;CUI Wen-yan;LIU Xiu-ju(The Second Hospital of Hebei Medical University,Shijiazhuang HEBEI 050000,China)

机构地区：[1]河北医科大学第二医院,河北石家庄050000

出　　处：《中国新药与临床杂志》2022年第11期641-645,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：河北省医学科学研究课题计划项目(20200978)。

摘　　要：玛巴洛沙韦是一种具有全新作用机制的抗流感病毒新药,作为Cap依赖性内切酶抑制剂,通过抑制流感病毒RNA聚合酶PA亚基的内切酶活性,特异性阻断流感病毒的增殖过程,用于治疗12岁及以上、流感症状不超过48 h的急性无并发症流感患者。玛巴洛沙韦相比于神经氨酸酶抑制剂具有服药次数少、抗病毒疗效快、不良反应少等优点,且可以快速缓解甲型流感成年患者的呼吸困难。Baloxavir marboxil is a new anti-influenza virus drug with a completely novel mechanism of action. As a Cap-dependent endonuclease inhibitor, it specifically blocks the proliferation of influenza virus by inhibiting the endonuclease activity of the PA subunit of the RNA polymerase of influenza virus. It is used to treat the acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 h. Compared with neuraminidase inhibitors, baloxavir marboxil has the advantages of fewer times of taking drugs, faster antiviral efficacy, fewer adverse reactions and so on, and it can quickly relieve the dyspnea of adult patients with influenza A.

关 键 词：玛巴洛沙韦 流感 人 治疗结果 安全 临床研究 

分 类 号：R978.7[医药卫生—药品]